Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50 Day Moving Average – Time to Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $5.86 and traded as high as $6.01. Karyopharm Therapeutics shares last traded at $5.89, with a volume of 148,612 shares.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on KPTI shares. HC Wainwright raised shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Monday, October 13th. Wall Street Zen raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, October 9th. Piper Sandler restated an “overweight” rating and set a $12.00 price target (down previously from $15.00) on shares of Karyopharm Therapeutics in a report on Thursday, October 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 1st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $15.40.

Karyopharm Therapeutics Trading Up 2.4%

The stock has a market capitalization of $100.42 million, a price-to-earnings ratio of -0.41 and a beta of 0.23. The firm’s fifty day moving average price is $5.86 and its 200 day moving average price is $5.36.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The business had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. On average, analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Baird Financial Group Inc. acquired a new position in Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $56,000. Silverback Asset Management LLC grew its holdings in shares of Karyopharm Therapeutics by 40.0% in the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics in the third quarter valued at approximately $164,000. Finally, Bank of America Corp DE increased its stake in Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).